- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05004350
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (NAUTICALCRC)
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Shankar Balaratnam
- Phone Number: +44 (0) 7770 542678
- Email: shankar.balaratnam@pierre-fabre.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
Beijing, Beijing, China, 100036
- Beijing Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Fujian Medical University - Fujian Provincial Cancer Hospital
-
Xiamen, Fujian, China, 361001
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Foshan, Guangdong, China, 528010
- The First People's Hospital of Foshan
-
Guangzhou, Guangdong, China, 510095
- Cancer Center of Guangzhou Medical University
-
Guangzhou, Guangdong, China, 510655
- The Sixth Affiliated Hospital Sun Yat-Sen University
-
Shantou, Guangdong, China, 515041
- Cancer Hospital affiliated to Shantou University Medical College
-
Shenzhen, Guangdong, China, 518036
- Peking University Shenzhen Hospital
-
-
Hebei
-
Baoding, Hebei, China, 071000
- The Affiliated Hospital of Hebei University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150040
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, China, 450008
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- Zhongnan Hospital of Wuhan University
-
Wuhan, Hubei, China, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Wuhan, Hubei, China, 430030
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital Central South University
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213003
- The First People's Hospital of Changzhou
-
-
Jiangxi
-
Ganzhou, Jiangxi, China, 341001
- First Affiliated hospital of GANNAN Medical University
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University
-
Nanchang, Jiangxi, China, 330006
- The Second Affiliated Hospital of Nanchang University
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University
-
-
Liaoning
-
Jinzhou, Liaoning, China, 121011
- The First Affiliated Hospital of Jinzhou Medical University
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
Shenyang, Liaoning, China, 110042
- Liaoning cancer Hospital & Institute
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710068
- Shaanxi Provincial People's Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Huashan Hospital Fudan University
-
Shanghai, Shanghai, China, 200032
- Zhongshan Hospital Fudan University
-
Shanghai, Shanghai, China, 200092
- Xinhua Hospital Affilliated to Shanghai Jiaotong University School of Medicine
-
Shanghai, Shanghai, China, 200120
- Shanghai East Hospital, Tongji University
-
-
Sichuan
-
Neijiang, Sichuan, China, 641000
- The Second People's Hospital of Neijiang
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital - Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital - Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Molecular Prescreening:
The following inclusion criteria must be met for a participant to be eligible to undergo molecular tumor prescreening:
- Chinese male or female participant with age ≥18 years at the time of informed consent.
- Histologically- or cytologically-confirmed colorectal cancer (CRC) that is metastatic.
- Eligible to receive cetuximab per Chinese approved label with regard to tumor Rat Sarcoma Viral Oncogene Homologue (RAS) mutation status (i.e. approved for Rat Sarcoma Viral Oncogene Homologue Wild Type(RAS wt) status).
- Able to provide a sufficient amount of representative tumor specimen for central prospective laboratory testing of B-RAF Proto-oncogene, Serine/threonine Kinase (BRAF) mutation status and also retrospective RAS wt status and Microsatellite Instability (MSI) testing.
Inclusion Criteria for Treatment Period:
The following inclusion criteria must be met for a participant to be eligible for this study:
- Chinese male or female participant with age ≥18 years at time of informed consent.
- Histologically or cytologically confirmed CRC that is metastatic and unresectable at time of study entry (i.e. not suitable for complete surgical resection at screening).
- Presence of a BRAF V600E mutation in tumor tissue previously determined by a local assay at any time before screening or by the central laboratory.
NOTE: Other protocol defined Inclusion criteria may apply
Exclusion Criteria for Molecular Prescreening:
Participants meeting any of the following criteria are not eligible to undergo molecular tumor prescreening:
- Prior anti-Epidermal Growth Factor Receptor (anti-EGFR) treatment
- More than two prior regimens in the metastatic setting.
- Known contraindication to receive cetuximab or irinotecan at the planned dose according to the most recent cetuximab and irinotecan local label.
- Known history of Gilbert's syndrome or is known to have any of the following genotypes: uridine 5'-diphospho-glucuronosyltransferase (UGT)1A1*6/*6, UGT1A1*28/*28 or UGT1A1*6/*28.
- Leptomeningeal disease.
Exclusion Criteria for Treatment Period:
- Prior treatment with any Proto oncogene Serine/threonine-Protein Kinase (RAF) inhibitor, cetuximab, panitumumab or other EGFR inhibitors.
- Symptomatic brain metastasis.
- Leptomeningeal disease.
- Use of any herbal medications/supplements or any medications or foods that are moderate or strong inhibitors or inducers of cytochrome P450 (CYP)3A4/5 ≤1 week before the start of study intervention.
- Known history of acute or chronic pancreatitis within 6 months before the start of study intervention.
NOTE: Other protocol defined Exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Encorafenib and cetuximab
Safety Lead-in (SLI) phase: 28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly Randomized (Phase II) phase: 28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly |
oral hard capsule
Other Names:
intravenous infusion
Other Names:
|
Experimental: Irinotecan and cetuximab or FOLFIRI and cetuximab
Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles. Irinotecan and cetuximab:
OR FOLFIRI and cetuximab:
|
oral hard capsule
Other Names:
intravenous infusion
Other Names:
Combination of: irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Lead-in Phase: Incidence of Dose Limiting Toxicities (DLTs) during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI)
Time Frame: Day 1 to Day 28
|
Day 1 to Day 28
|
|
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Defined as the time from the date of randomization to the earliest documented disease progression as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., or death due to any cause
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Lead-in Phase: Type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03
Time Frame: Informed consent through to study completion, approximately from 18 to 35 months
|
Informed consent through to study completion, approximately from 18 to 35 months
|
|
Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of physical examinations
Time Frame: Day 1 through to study completion, approximately from 18 to 35 months
|
Standard physical examinations on cardiovascular, respiratory, gastrointestinal, dermatological, ophthalmological and neurological systems will be performed and will be evaluated based on normal/abnormal and clinical significance observations.
Number of participants with TEAEs related to abnormal or clinical significance observations to the physical examinations after the start of study drug will be reported.
|
Day 1 through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes in vital signs from baseline of vital sign examinations.
Time Frame: Day 1 through to study completion, approximately from 18 to 35 months
|
Clinically notable elevated values: Systolic blood pressure (BP): ≥ 160 mmHg and an increase ≥ 20 mmHg from baseline; Diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; Heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; Weight (kg) increase from baseline of ≥ 10%; Body temperature(°C) ≥ 37.5°C).
Clinically notable low values: Systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; Diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; Heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; Weight: ≥ 20% decrease from baseline; Body temperature [°C]: ≤ 36 °C.
Number of participants with TEAEs related to notable changes to the vital signs after the start of study drug will be reported.
|
Day 1 through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of 12-lead electrocardiograms (ECGs)
Time Frame: Day 1 through to study completion, approximately from 18 to 35 months
|
12-lead ECGs will be obtained using an internationally recognized 12-lead cardiograph.
Clinically notable ECG values: QT (ms) and QT interval (ms) corrected for heart rate using Fridericia's formula (QTcF) intervals (ms) : increase from baseline > 30 ms; increase from baseline > 60 ms, new > 450 ms, new > 480 ms, new > 500 ms.
Heart rate (beats/min) : increase from baseline > 25% to a value > 100 bpm, decrease from baseline > 25% and to a value < 50 bpm.
Number of participants with TEAEs related to abnormal or notable changes to ECG parameters after the start of study drug will be reported.
|
Day 1 through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Incidence of treatment-emergent adverse events (TEAEs) related to notable changes in clinical safety laboratory parameters from baseline.
Time Frame: Day 1 through to study completion, approximately from 18 to 35 months
|
Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 4.03 were graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated.
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Death.
Clinically notable shift is defined as a worsening from baseline by at least 2 grades, or to grade 3 or above.
|
Day 1 through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Incidence of development of of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma by dermatological examinations
Time Frame: Screening (Day -28 to -1) through to study completion, approximately from 18 to 35 months
|
This is to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma, as these have been reported to occur with selective BRAF inhibitor treatment.
This assessment will be performed at screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit.
|
Screening (Day -28 to -1) through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Performance status assessment using the Eastern Co-operative Oncology Group (ECOG) performance status scale
Time Frame: Screening (Day -28 to -1) through to study completion, approximately from 18 to 35 months
|
Scale with a range from 0 to 5 with lower score mean a lower functional impairment, 5 corresponding to death
|
Screening (Day -28 to -1) through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events (AEs)
Time Frame: Day 1 until end of treatment, approximately 1 year
|
Day 1 until end of treatment, approximately 1 year
|
|
Safety Lead-in Phase: Plasma concentrations of encorafenib
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Serum concentrations of cetuximab
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase; Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib area under curve (AUC) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab area under curve (AUC) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib minimum concentration (Cmin) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab minimum concentration (Cmin) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib maximum concentration (Cmax) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab maximum concentration (Cmax) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Safety Lead-in Phase: Objective response rate (ORR)
Time Frame: Day 1 through to study completion, approximately from 18 to 35 months
|
Objective response rate (ORR) defined as the proportion of participants with a best overall best response of either complete response (CR) or partial response (PR) as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
|
Day 1 through to study completion, approximately from 18 to 35 months
|
Safety Lead-in Phase: Duration of Response (DOR) (months); defined for responders complete response (CR) or partial response (PR) only, is duration of time from the date of the first documented response to the earliest date of disease progression
Time Frame: Day 1 through to study completion, approximately from 18 to 35 months
|
Duration of response, defined as the time from first documented response (complete response or partial response) to the earliest date of disease progression as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death due to underlying disease.
|
Day 1 through to study completion, approximately from 18 to 35 months
|
Randomized Phase 2: Progression-free survival (PFS)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Progression-free survival defined as the interval of time between the date of randomization to the earliest date of disease progression, as determined by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Overall Response Rate (ORR)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Overall response rate (for confirmed and unconfirmed responses) defined as the proportion of participants with a confirmed (resp.
unconfirmed) best overall response of either complete response or partial response, as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Duration of Response (DOR)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Duration of response defined as the time from the date of the first documented response (complete response or partial response) to the earliest date of disease progression, as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Disease control rate (DCR)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Disease control rate (DCR), defined as the proportion of participants with a best overall response of either complete response, partial response or stable disease (SD), as determined by Blinded (to treatment received) Independent Central Review (BICR) and investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Time to Response (TTR)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Time to Response (for confirmed and unconfirmed responses) is defined as the time between date of randomization until first documented response of complete response (CR) or partial response (PR).
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Overall Survival (OS)
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Overall survival is defined as time from randomization until date of death due to any cause
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Type and severity of adverse events (AEs) and serious adverse events (SAEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03
Time Frame: Informed consent date through to study completion, approximately from 12 to 29 months
|
Informed consent date through to study completion, approximately from 12 to 29 months
|
|
Randomized Phase 2: Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes from baseline of physical examinations
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Standard physical examinations on cardiovascular, respiratory, gastrointestinal, dermatological, ophthalmological and neurological systems will be performed and will be evaluated based on normal/abnormal and clinical significance observations.
Number of participants with TEAEs related to abnormal or clinical significance observations to the physical examinations after the start of study drug will be reported
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Incidence of treatment-emergent adverse events (TEAEs) related to notable changes in vital signs from baseline.
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Clinically notable elevated values: Systolic blood pressure (BP): ≥ 160 mmHg and an increase ≥ 20 mmHg from baseline; Diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; Heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; Weight (kg) increase from baseline of ≥ 10%; Body temperature(°C) ≥ 37.5°C).
Clinically notable low values: Systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; Diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; Heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; Weight: ≥ 20% decrease from baseline; Body temperature [°C]: ≤ 36 °C.
Number of participants with TEAEs related to notable changes to the vital signs after the start of study drug will be reported.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Incidence of treatment-emergent adverse events (TEAEs) related to notable or abnormal changes to electrocardiogram evaluations from baseline
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
12-lead ECGs will be obtained using an internationally recognized 12-lead cardiograph.
Clinically notable ECG values: QT (ms) and QT interval (ms) corrected for heart rate using Fridericia's formula (QTcF) intervals (ms): increase from baseline > 30 ms; increase from baseline > 60 ms, new > 450 ms, new > 480 ms, new > 500 ms; Heart rate (beats/min): increase from baseline > 25% to a value > 100 bpm, decrease from baseline > 25% and to a value < 50 bpm.
Number of participants with TEAEs related to abnormal or notable changes to ECG parameters after the start of study drug will be reported.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Incidence of treatment-emergent adverse events (TEAEs) related to notable changes in clinical safety laboratory parameters from baseline.
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 4.03 were graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated.
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Death.
Clinically notable shift is defined as a worsening from baseline by at least 2 grades, or to grade 3 or above.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Incidence of development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma by dermatological examinations
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
This is to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and new primary melanoma, as these have been reported to occur with selective BRAF inhibitor treatment.
This assessment will be performed at screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: To determine the performance status using the Eastern Co-operative Oncology Group (ECOG) performance status scale.
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Scale with a range from 0 to 5 with lower score mean a lower functional impairment, 5 corresponding to death
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: To determine if there is any change from baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire scores
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
EORTC QLQ-C30 consist of nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, nausea and vomiting); and a global health and Quality of Life (QoL) scale.
Each scale in the questionnaire will be scored (0 to 100).
High scores represents a high health/quality of life
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: To determine if there is any change from baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire scores.
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).
The descriptive system has five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each is rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that describes the participant's health state.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: To determine if there is any change from baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) questionnaire scores
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
FACT-C is a validated quality of life questionnaire for patient reported outcome assessment.
FACT-C consists of 36 items, presented on a five-point Likert scale, in four domains of well-being (physical, emotional, social and functional) and the Colorectal Cancer Subscale.
Higher score reflects a better quality of life.
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: To determine if there is any changes in the Patient Global Impression of Change (PGIC) questionnaire scores.
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
PGIC will ask participants to evaluate their CRC symptoms since starting study intervention according to a seven-point verbal rating scale (VRS): 1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Plasma concentrations of encorafenib
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Serum concentrations of cetuximab
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2; Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib area under curve (AUC) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab area under curve (AUC) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib minimum concentration (Cmin) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab minimum concentration (Cmin) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Pharmacokinetic (PK) parameter derived from plasma concentration of encorafenib maximum concentration (Cmax) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Pharmacokinetic (PK) parameter derived from serum concentration of cetuximab maximum concentration (Cmax) in Chinese participants
Time Frame: Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
Day 1 of Cycles 1 and 2; Each cycle = 28 days
|
|
Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data
Time Frame: Day 1 through to study completion, approximately from 12 to 29 months
|
Day 1 through to study completion, approximately from 12 to 29 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Randomized Phase 2: Changes from baseline in blood Carcinoembryonic Antigen (CEA) and Cancer Antigen 19-9 (CA19-9) at the beginning of each cycle and at the end of treatment
Time Frame: Screening (Day -28 to -1) through to study completion, approximately from 12 to 29 months
|
Screening (Day -28 to -1) through to study completion, approximately from 12 to 29 months
|
Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening
Time Frame: Screening (Day -28 to Day -1)
|
Screening (Day -28 to Day -1)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Shen Lin, MD, Peking University Cancer Hospital & Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Topoisomerase I Inhibitors
- Fluorouracil
- Irinotecan
- Cetuximab
Other Study ID Numbers
- W00090GE202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on Encorafenib
-
Pierre Fabre MedicamentEuropean Organisation for Research and Treatment of Cancer - EORTCActive, not recruitingMelanomaSpain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
-
University Health Network, TorontoActive, not recruiting
-
PfizerTerminatedBrain MetastasesUnited States, Belgium, Australia, Argentina, Italy
-
PfizerPierre Fabre LaboratoriesTerminated
-
Array BioPharmaTerminatedMelanomaCanada, Spain, Australia, Switzerland, Germany, United States
-
Leiden University Medical CenterPierre Fabre LaboratoriesRecruitingMelanoma Stage III | In-Transit Metastasis of Cutaneous MelanomaNetherlands
-
National Cancer Institute (NCI)RecruitingHairy Cell LeukemiaUnited States
-
Pierre Fabre Pharma GmbHPierre Fabre Pharma Austria; Pierre Fabre Pharma AGRecruitingMelanoma Stage IV | Melanoma Stage IIIAustria, Germany, Switzerland
-
University of UtahVerastem, Inc.Recruiting
-
PfizerRecruitingSolid TumorsUnited States, Spain, Canada, Italy, Australia, Hungary, Netherlands, United Kingdom, Germany, Brazil, Korea, Republic of, Portugal, France, Japan, Israel, Slovakia, Czechia